ZA201403085B - Genetically modified major histocompatibility complex mice - Google Patents
Genetically modified major histocompatibility complex miceInfo
- Publication number
- ZA201403085B ZA201403085B ZA2014/03085A ZA201403085A ZA201403085B ZA 201403085 B ZA201403085 B ZA 201403085B ZA 2014/03085 A ZA2014/03085 A ZA 2014/03085A ZA 201403085 A ZA201403085 A ZA 201403085A ZA 201403085 B ZA201403085 B ZA 201403085B
- Authority
- ZA
- South Africa
- Prior art keywords
- genetically modified
- human
- major histocompatibility
- histocompatibility complex
- modified major
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552587P | 2011-10-28 | 2011-10-28 | |
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| PCT/US2012/062042 WO2013063346A1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201403085B true ZA201403085B (en) | 2025-07-30 |
Family
ID=47178940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/03085A ZA201403085B (en) | 2011-10-28 | 2014-04-25 | Genetically modified major histocompatibility complex mice |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9615550B2 (enExample) |
| EP (4) | EP3262932B1 (enExample) |
| JP (4) | JP6154391B2 (enExample) |
| KR (3) | KR102295746B1 (enExample) |
| CN (3) | CN113564188B (enExample) |
| AU (3) | AU2012324016C1 (enExample) |
| BR (1) | BR112014009259A2 (enExample) |
| CA (3) | CA3074400C (enExample) |
| CY (2) | CY1119657T1 (enExample) |
| DK (2) | DK2770821T3 (enExample) |
| ES (3) | ES2962287T3 (enExample) |
| HK (1) | HK1249712B (enExample) |
| HR (2) | HRP20171761T1 (enExample) |
| HU (2) | HUE035652T2 (enExample) |
| IL (3) | IL232097A (enExample) |
| LT (2) | LT3262932T (enExample) |
| MX (3) | MX355725B (enExample) |
| MY (2) | MY178723A (enExample) |
| NZ (1) | NZ734532A (enExample) |
| PL (2) | PL3262932T3 (enExample) |
| PT (2) | PT2770821T (enExample) |
| RS (2) | RS59082B1 (enExample) |
| SG (2) | SG10201603188SA (enExample) |
| SI (2) | SI2770821T1 (enExample) |
| SM (2) | SMT201700576T1 (enExample) |
| WO (1) | WO2013063346A1 (enExample) |
| ZA (1) | ZA201403085B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2818478T1 (sl) | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| CA2902543A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| JP6492095B2 (ja) | 2013-10-15 | 2019-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化ｉｌ−１５動物 |
| US10278373B2 (en) | 2013-10-18 | 2019-05-07 | Taiho Pharmaceutical Co., Ltd. | HLA class I-expressing non-human animal |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| US20150143559A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| RS60398B1 (sr) | 2014-04-08 | 2020-07-31 | Regeneron Pharma | Ne-humane životinje sa humanizovanim fc-gama receptorima |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| BR112017010793A2 (pt) | 2014-11-24 | 2017-12-26 | Regeneron Pharma | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| ES2841353T3 (es) * | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| WO2016094679A1 (en) | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
| ES2950399T3 (es) * | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| CN109640644B (zh) | 2016-06-03 | 2021-10-26 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| DK3687287T5 (da) * | 2017-09-29 | 2024-08-26 | Regeneron Pharma | Gnavere, udtrykkende humaniseret c1q-kompleks |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| EP4534560A3 (en) | 2018-03-24 | 2025-06-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| IL277355B2 (en) | 2018-03-26 | 2025-01-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| JP2022527061A (ja) * | 2019-03-25 | 2022-05-30 | ゼノセラピューティクス インコーポレイテッド | ヒト化された、オーダーメイドされた、指定された病原体を含まない（非ヒト）ドナーから移植するための、個別化された細胞、組織、及び臓器、ならびにそれらに関連する方法及び製品 |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子１２遺伝子座を含む非ヒト動物 |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| EP4087392A4 (en) * | 2020-01-10 | 2024-02-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX |
| EP4262373A1 (en) | 2020-12-16 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| US20260114433A1 (en) * | 2020-12-16 | 2026-04-30 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human beta2-microglobulin within donor cells, tissues, or organs |
| CN116981357A (zh) | 2021-03-31 | 2023-10-31 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| US20250185635A1 (en) * | 2022-03-21 | 2025-06-12 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin and mhc loci |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| CA3265746A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF A HUMAN CELLULAR IMMUNE SYSTEM |
| EP4654982A1 (en) | 2023-01-27 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
| TW202520975A (zh) * | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| KR20260074976A (ko) | 2023-09-19 | 2026-05-27 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 펩티드 및 이의 용도 |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| CN122438694A (zh) | 2023-12-19 | 2026-07-21 | 瑞泽恩制药公司 | Foxp3肽及其用途 |
| WO2025178991A1 (en) | 2024-02-21 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Splicing factor gene mutation-associated neoantigenic peptides and uses thereof |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2026006734A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development |
| WO2026006724A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Prame off-target peptides and uses thereof |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026096736A1 (en) | 2024-10-31 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Rodents expressing humanized polymeric immunoglobulin receptor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC ANIMALS HAVING TARGET LYMPHOCYTA TRANSDUCTION GENES. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| EP0910409A4 (en) | 1996-03-05 | 2003-03-19 | Scripps Research Inst | RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| DE69917541T2 (de) * | 1998-02-17 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | H2-o modifizierte transgene tiere |
| WO2001027291A1 (en) * | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| US7745690B2 (en) | 2004-03-09 | 2010-06-29 | Nagoya Industrial Science Research Institute | Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
| NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| JP2010526066A (ja) * | 2007-04-23 | 2010-07-29 | シェーリング コーポレイション | 抗ｍｄｌ−１抗体 |
| EP2262898B1 (en) | 2008-03-07 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
| DK3241435T3 (da) * | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| WO2014195159A1 (en) * | 2013-06-03 | 2014-12-11 | Theravectys | Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence |
| US10278373B2 (en) * | 2013-10-18 | 2019-05-07 | Taiho Pharmaceutical Co., Ltd. | HLA class I-expressing non-human animal |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
-
2012
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active Active
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 CA CA3074400A patent/CA3074400C/en active Active
- 2012-10-26 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 CA CA3311022A patent/CA3311022A1/en active Pending
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 CN CN202110831383.7A patent/CN113564188B/zh active Active
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 SM SM20170576T patent/SMT201700576T1/it unknown
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active Active
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active Active
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en not_active Ceased
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 MX MX2020010763A patent/MX391222B/es unknown
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 SM SM20190478T patent/SMT201900478T1/it unknown
- 2012-10-26 MX MX2017013466A patent/MX376167B/es unknown
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
- 2014-04-25 ZA ZA2014/03085A patent/ZA201403085B/en unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/en unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
-
2026
- 2026-03-04 US US19/556,620 patent/US20260182550A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010763A (es) | Ratones con complejo principal de histocompatibilidad modificado geneticamente. | |
| MX355726B (es) | Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii. | |
| CY1121223T1 (el) | Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
| CY1121979T1 (el) | Ποντικια που εκφραζουν ανθρωποποιημενους τ-λεμφοκυτταρικους συνυποδοχεις | |
| EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
| AU2019264610A1 (en) | Genetically modified animals and methods for making the same | |
| MX2016003636A (es) | Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. | |
| MX2017006802A (es) | Animales no humanos que expresan el complejo cd3 humanizado. | |
| MY187624A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor | |
| MX2022001201A (es) | Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos. | |
| AU2013312359A8 (en) | Genetically modified non-human animals and methods of use thereof | |
| MX2012012689A (es) | Anticuerpos que tienen inmunogenicidad reducida en un ser humano. | |
| HK1203761A1 (en) | Humanized il-7 rodents | |
| MX353134B (es) | Ratones con receptor de linfocitos t modificados geneticamente. | |
| MX374929B (es) | RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO. | |
| WO2014122035A3 (en) | Induced dendritic cells and uses thereof | |
| SG10201908800YA (en) | Non-human animals having humanized fc-gamma receptors | |
| MX2021000586A (es) | Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii. | |
| WO2012148538A3 (en) | Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin | |
| TH168664A (th) | หนูที่มีเมเจอร์ ฮิสโตคอมแพทาบิลิตี้ คอมเพลกซ์ซึ่งถูกดัดแปลงทางพันธุกรรม |